HISTORICAL FACTS: Podd | History Defined

How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks?

Insulet has notably underperformed the Medical Devices industry over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Barchart · Sep 24

Is Wall Street Bullish or Bearish on Insulet Stock?

Insulet has considerably underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Barchart · Aug 25

Insulet's Q2 2026 Earnings: What to Expect

Insulet will release its second-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

Barchart · Jul 22

What Are Wall Street Analysts' Target Price for Insulet Stock?

Insulet has underperformed the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.

Barchart · Feb 18

Is Insulet Stock Underperforming the Nasdaq?

Although Insulet has underperformed the Nasdaq recently, analysts remain highly optimistic about the stock’s prospects.

Barchart · Dec 16, 2025

Insulet Stock: Is Wall Street Bullish or Bearish?

Insulet has outperformed the broader market over the past year, and analysts remain strongly bullish on the company’s trajectory.

Barchart · Nov 20, 2025

What to Expect From Insulet's Next Quarterly Earnings Report

Insulet will release its third-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

Barchart · Oct 24, 2025

Is Insulet Stock Outperforming the S&P 500?

Insulet has outperformed the S&P 500 over the past year, and analysts are highly optimistic about the stock’s prospects.

Barchart · Sep 24, 2025

Insulet Stock: Analyst Estimates & Ratings

Insulet has significantly outpaced the broader market over the past year, and analysts remain very bullish on the stock’s prospects.

Barchart · Aug 26, 2025

Insulet Lifts Annual Forecast On Increased Adoption For Insulin Pump Omnipod 5

Insulet Corporation (NASDAQ:PODD) reported second-quarter adjusted earnings of $1.17 per share, beating the consensus of 92 cents.

Benzinga · Aug 7, 2025